+33 1 76 70 47 90
/
creativ@creativ-ceutical.com
Home
Who We Are
About Us
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Japan
Publications
News & Events
Careers
Contact
Home
Who We Are
About Us
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Japan
Publications
News & Events
Careers
Contact
[PMH26] A studies-based private insurance budget impact analysis of buprenorphine / naloxone film and tablet formulations
Home
Publications
[PMH26] A studies-based private insurance budget impact analysis of buprenorphine / naloxone film and tablet formulations
Back Home
[PMH26] A studies-based private insurance budget impact analysis of buprenorphine / naloxone film and tablet formulations
2014 Value in health
Clay, E. | Khemiri, A. | Ruby, J. | Aballea, S. | Zah, V. |
Volume: 17, Issue: 3, Pages: A213,
analysis, budget impact,
https://www.doi.org/10.1016/j.jval.2014.03.1245
